Nippon Boehringer Ingelheim And Lilly Japan Launch Tradjenta
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Nippon Boehringer Ingelheim and Kobe-based Eli Lilly Japan have launched Tradjenta (linagliptin), a DPP-4 inhibitor for patients with type 2 diabetes in Japan